

Supplementary Dataset for

Development of versatile non-homologous end joining-based knock-in module for genome editing

Shun Sawatsubashi^{1*}, Yudai Joko¹, Seiji Fukumoto¹, Toshio Matsumoto¹, Shigeo S. Sugano^{2,3*}

¹ Department of Molecular Endocrinology, Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan

² Ritsumeikan Global Innovation Research Organization, Ritsumeikan University, Shiga, Japan

³ PRESTO, Japan Science and Technology Agency, Japan


* Corresponding authors

This PDF files includes :

Supplementary Figs. S1 to S5


Supplementary Tables S1 to S5

Supplementary Information (including the uncropped gel and blot source data)




Supplementary Fig. S1 Knock-in efficiency using a pre-linearized donor vector.

(a) Schematic representation of knock-in strategy mediated a pre-linearized donor vector. The *PURO*-cassette vector was digested with *ApaI* enzyme. (b) The efficiency of knock-in events using linearized or circular donor vector with the condition optimized in Fig. 2.




Supplementary Fig. S3 Southern blot analyses of the genomes of clones which are described in Fig. 3a.

(a) Schematic image of the experimental design of southern blotting. The specific probe for a donor vector pVKG1-Puro was shown as “Probe.” Expected sizes of the genome fragment digested by three restriction enzymes were shown. (b-d) Southern blot analysis of the genome of knock-in clones digested by NcoI (b), BsrGI (c), and PstI (d). #6, #18 were clones categorized as “random integrations” (Amplicon 6 positive). #1 and #29, which were red-colored, were clones categorized as “no random integrations” (Amplicon 6 negative). WT shows the analysis of the HaCaT cells without transfection. Clone numbers are corresponding to those in Figure 3.



Supplementary Fig. S4 Simultaneous knock-in of two donor vectors using VIKING method.

(a-c) Simultaneous knock-in of two different vectors. The pVKG1-PURO and pVKG1-BSD were used as donor vectors. (a) Confirmation of directions of integrated donor vectors by PCR analysis. Schematic PCR products were written (Amplicon 1-6). Schematic PCR products are written (Amplicon 1-6). If Amplicon 1 and Amplicon 2 were amplified, the insertion of the donor vector is defined as “the forward direction.” On the other hand, if Amplicon 3 and Amplicon 4 were amplified, it is defined as “the reverse direction.” (b) Direct sequencing analysis of the junctions of the knock-in sites. (c) Immunoblot analyses of isolated clones. α Hsp90 and $\alpha\beta$ -ACT were used as loading controls.



Supplementary Fig. S5 Isolation of knock-in/knock-out clones in *HR* locus using HaCaT cells.

(a) Confirmation of directions of integrated donor vectors in *HR* locus by PCR analysis. Schematic PCR products were written (Amplicon 1-6). (b) (Upper) Sequences for cleaving pVKG1-PURO vector (the donor vector) and *HR* locus in the genome. The exact target sites of gRNA were underlined. The PAM sequences were colored in red

and shown in bold. (Lower) The predicted sequence of knock-in products, in which the cleaved donor vector was precisely integrated into the target site. The two possible directions of insertion (forward and reverse) were shown. The cleavage site by Cas9 was shown in slash. (c) The summary of direct sequencing analyses of knock-in clones. The junction sites of the knock-in clones were shown. (d) Sequences of the *HR* locus in the genome of knock-in cell lines analyzed by direct sequencing of PCR product. (e) Immunoblot analyses of isolated clones. Immunoprecipitated products using α HR (abcam) antibody (Upper) and cell lysates (Lower) were analyzed using α HR (R&D), α Hsp90 and α β -ACT antibodies.

Supplementary Table S1 Design of VKG1 sequence using CRISPRdirect

Using Homo sapiens genome data (hg19), potential off targets of all the gRNA target sequences in the pUC19 vector were analyzed by CRISPRdirect³⁵.

Column1-2: the position of nucleotide and direction of the strand in pUC19. The sequence of pUC19 was obtained from Addgene Plasmid #50005.

Column4: the target sequences of gRNA with PAM. Column5-7: Number of off targets which match the gRNA target sequence of PAM proximal 20 mer (hit_20mer), 12mer (hit_12mer), and 8mer (hit_8mer).

The gRNA target with fewest off target was shown in yellow and its 18 nt truncated version was defined as VKG1.

Ref 35. Naito Y, Hino K, Bono H, Ui-Tei K. CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. *Bioinformatics* **31**, 1120-1123 (2015).

# start	end	strand	sequence	hit_20mer	hit_12mer	hit_8mer	
2642	2664	-	ccgaacgaccgagcgcagcgagt	0	2	82	VKG1 18nt
1287	1309	+	ttacttctgacaacgatcgagg	0	0	83	
1398	1420	-	ccaacgacgagcgtgacaccac	0	0	108	
25	47	-	ccccgcgcttgccgattcatt	0	2	168	
672	694	-	ccgaacgacgagcgaaggg	0	1	172	
1651	1673	+	tcgtagtattacacgagggg	0	1	194	
568	590	-	ccgctgacgcccctgacggct	0	3	195	
2195	2217	+	aagacgatagttaccgataagg	0	2	228	
2372	2394	+	cggaacgagagcgacgaggg	0	3	232	
27	49	-	ccgctggtgcccattcattaa	0	0	250	
2509	2531	-	ccagcaacgccccttttaacgg	0	1	258	
327	349	-	cctggcttacccaacttaacg	0	2	272	
158	180	-	ccgctcgtatgtgtggaat	0	1	280	
1124	1146	-	ccgtattgaccccgcgaagc	0	0	281	
1645	1667	-	cccgtatcgtattatcacacg	0	1	282	
2358	2380	+	gtaagcggcagggcgaacagg	0	0	287	
1646	1668	-	ccgtatcgtattatcacacga	0	2	295	
1650	1672	+	atcgtattatcacacgaggg	0	2	295	
15	37	+	aaccgcctctcccgcgttgg	0	2	299	
1004	1026	+	acgagtggtttacatggaactg	0	2	302	
2600	2622	-	ccgtattacccttgagtgag	0	1	307	
1116	1138	+	gtattaccgtattgacccgg	0	0	309	
26	48	-	cccgcgctggccgattcatta	0	3	323	
481	503	+	gccgtattcacaccgataagg	0	0	330	
5	27	-	ccaatacgaacccctctccc	0	0	331	
2064	2086	+	cttctagtgtaccgtagttagg	0	1	341	
2168	2190	+	taagtcgtgtctaccgggtgg	0	0	351	
735	757	+	ataatgcttcttagacgtcagg	0	3	356	
298	320	+	tcgttttaacaagctcgtactg	0	0	361	
467	489	-	ccttacgcactgtgctgattt	0	0	369	
2371	2393	+	tcggaacgagagcgcacgagg	0	7	401	
269	291	-	ccggctaccgagctgaattcac	0	4	402	
398	420	-	ccgacacgacgccctccaac	0	2	417	
1284	1306	+	aacttactctgacacgatcgg	0	1	443	
326	348	-	ccctgcttaccacaactaac	0	2	447	
2571	2593	-	cctgcttaccctgattctgt	0	2	450	
1352	1374	+	tgtaactcctgattgctggg	0	2	457	
1351	1373	+	atgtaactcctgattgctggg	0	1	461	
268	290	-	cccggtaaccgagctgaattca	0	5	469	
2430	2452	-	cctgtcgggtttcccaactctg	0	0	486	
2158	2180	-	ccagtgccgataagtcgtctt	0	0	491	
45	67	+	attaatcgagctggcagcaggg	0	3	496	
374	396	+	cagctggcgaatagcgaagagg	0	3	497	
1361	1383	-	ccttgatggtgggaaccgagc	0	7	503	
990	1012	+	gatcagttgggtgacaggtggg	0	2	512	
220	242	-	ccatgattcggcaagccttgc	0	1	527	
2464	2486	+	gattttgtgatcctgtaggg	0	4	528	
397	419	-	cccgcacgatgcccttcccaa	0	1	542	
431	453	-	cctgaatggcgaatggcctga	0	2	552	
4	26	-	ccaatacgaacccctctccc	0	4	554	
1203	1225	+	acagaaaagcattcagatgg	0	2	555	
1649	1671	+	tatcgtattatctacacgagg	0	4	561	
2275	2297	-	cctacaccgaactgagataccta	0	2	563	
2355	2377	-	ccggtaacgcccagggcgaac	0	7	566	
1642	1664	-	cctccgtatcgtattatctac	0	0	569	
1117	1139	+	tattaccgtattgacccggg	0	0	575	
57	79	+	ggcacgacaggttcccactgg	0	3	575	
276	298	-	ccgagctcgaattcaactggcgt	0	2	587	
2465	2487	+	attttgtgatcctgtaggg	0	2	587	
1641	1663	-	ccctccgtatcgtattatcta	0	0	592	
1854	1876	-	ccttaactgagtttcttcca	0	4	594	
2347	2369	+	acaggtatccgtaagcggcagg	0	4	597	
919	941	-	cctttttcggcatttgcctt	0	1	618	
299	321	+	cgttttacaactcgtgactggg	0	0	646	
2466	2488	+	ttttgtgatcctgtagggg	0	2	651	
2343	2365	+	gggacaggtatccgtaagcgg	0	1	659	
363	385	-	cccccttccagctggcgtaa	0	3	665	
2220	2242	+	cagcggctgggctaacggggg	0	6	688	
2463	2485	+	cgattttgtgatgctcagg	0	1	696	
267	289	-	ccccgggtaccgactcgaattc	0	2	701	
989	1011	+	agatcagttgggtcagcagttg	0	6	703	
1588	1610	-	ccggtgagcgtggctcgcggt	0	4	710	
365	387	-	cccttccgacgtggcgtata	0	7	722	
762	784	+	acttttgggaaatgctgcgg	0	5	735	
1061	1083	-	ccccgaagaacgtttccaatga	0	0	737	
579	601	-	ccctgacggcttctctctccc	0	3	748	
580	602	-	cctgacggcttctctctccc	0	1	756	
366	388	-	cccttccagctggcgtatag	0	9	757	
1853	1875	-	cccttaactgagtttctgtcc	0	2	769	

Supplementary Table S2 Direct sequencing analysis of Knock-in cell lines

The sequences of PCR amplicon 1 - 4 in Fig.3B, which were analyzed by direct sequencing, were shown. The predicted sequences with forward and reverse direction were shown in colored sequences. PAM sequences were shown with red and bold. The indel were colored with red. The predicted sequences show the sequences with precise knocked-in (see also Supplementary Fig. S2).

Clone	Direction (Forward, Reverse)	Upstream (VDR genomic DNA)	Upstream (Plasmid DNA)	indel size	Downstream (VDR genomic DNA)	Downstream (Plasmid DNA)	indel size	Amplicon 6
		Predicted sequence (Forward)	CATGAAGCGGAAGGCCTATTACCTGCC CCTT CA/		GACCGAGCGCAGCGAGTCAGTG	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTTCGGCTGCGGCAGCGGATCAGCTCACTCAAAG	
		Predicted sequence (Reverse)	CATGAAGCGGAAGGCCTATTACCTGCC CCTT CA/		/GTTCGGCTGCGGCAGCGGAT	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GACCGAGCGCAGCGAGTCAGTG	
#1	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	0/0	negative
#5	Reverse	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCAGCGGAT	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GACCGAGCGCAGCGAGTCAGTG	0/0	negative
#9	Reverse	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCAGCGGAT	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GACCGAGCGCAGCGAGTCAGTG	0/0	negative
#12	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGC-----/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	-12/0	negative
#14	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	0/0	negative
#15	Reverse	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCAGCGGAT	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GACCGAGCGCAGCGAGTCAGTG	0/0	negative
#16	Reverse	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCAGCGGAT	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GACCGAGCGCAGCGAGTCAGTG	-2/0	negative
#17	Reverse	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCAGCGGAT	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/-----AGCGAGTCAGTG	-4/-10	negative
#21	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	0/0	negative
#26	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	0/0	negative
#29	Reverse	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCAGCGGAT	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GACCGAGCGCAGCGAGTCAGTG	0/0	negative
#30	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	0/0	negative
#33	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGC-----/	/-----AGCTCACTCAAAG	-23/-23	negative
#35	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGG-----/	/GTTCGGCTGCGGCAGCGGATCAGCTCACTCAAAG	-10/+1	negative
#38	Reverse	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/A	/GTT CGG CTGCGGCAGCGGAT	+1/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GACCGAGCGCAGCGAGTCAGTG	0/0	negative
#40	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	-2/0	negative
#41	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGT-----/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	-27/0	negative
#44	Forward	CATGAAGCGGAAGGCCTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGTCAGTG	0/0	GTCGGTTGCCTTGGTGATGCGGCAGTCCCGT/	/GTT CGG CTGCGGCAGCGGATCAGCTCACTCAAAG	0/0	negative

Supplementary Table S3 Direct sequencing of additional knock-in clones

The sequences of knock-in clones in addition to the supplementary fig.2, which were analyzed by direct sequencing, were shown. The predicted sequences with forward and reverse direction were shown in colored sequences. PAM sequences were shown with red and bold. The indel were colored with red. The predicted sequences show the sequences with precise knocked-in (see also Supplementary Fig. S2).

Clone	Upstream (VDR genomeDNA)	Upstream (Plasmid DNA)	indel size	Downstream (VDR genomeDNA)	Downstream (Plasmid DNA)	indel size	Amplicon 6
Predicted sequence (Forward)	CATGAAGCGGAAGGCACTATTACCTGCC CCT CA/	/GACCGAGCGCAGCGAGT CAGTG		GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GTT CGG CTGCGGCGAGCGGTATCAGCTCACTCAAAG		
Predicted sequence(Reverse)	CATGAAGCGGAAGGCACTATTACCTGCC CCT CA/	/GTT CGG CTGCGGCGAGCGGTAT		GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG		
#2	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#3	n. d.	n. d.		n. d.	n. d.		positive
#4	n. d.	n. d.		n. d.	n. d.		negative
#6	n. d.	n. d.		n. d.	n. d.		positive
#7	n. d.	n. d.		n. d.	n. d.		positive
#8	n. d.	n. d.		n. d.	n. d.		negative
#10	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GTT CGG CTGCGGCGAGGAGTATCAGCTCACTCAAAG	0/0	negative
#11	n. d.	n. d.		n. d.	n. d.		positive
#13	n. d.	n. d.		n. d.	n. d.		positive
#18	n. d.	n. d.		n. d.	n. d.		positive
#19	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GTT CGG CTGCGGCGAGGAGTATCAGCTCACTCAAAG	0/0	negative
#20	n. d.	n. d.		n. d.	n. d.		positive
#22	n. d.	n. d.		n. d.	n. d.		negative
#23	n. d.	n. d.		n. d.	n. d.		negative
#24	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#25	n. d.	n. d.		n. d.	n. d.		positive
#27	n. d.	n. d.		n. d.	n. d.		positive
#28	n. d.	n. d.		n. d.	n. d.		negative
#31	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/A	/GTT CGG CTGCGGCGAGCGGTAT	+1/0	GTCGG-----/	/-----CAAAG	-42/-46	negative
#32	n. d.	n. d.		n. d.	n. d.		positive
#34	n. d.	n. d.		n. d.	n. d.		negative
#36	n. d.	n. d.		n. d.	n. d.		negative
#37	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/A	/GTT CGG CTGCGGCGAGCGGTAT	+1/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#39	n. d.	n. d.		n. d.	n. d.		positive
#42	n. d.	n. d.		n. d.	n. d.		negative
#43	n. d.	n. d.		n. d.	n. d.		positive
#45	CATGAAGCGGAAGGCACT-----/	/--(412bp)--CTCGCTTAACGCTAGGATGGATGTTTT	-17/-412	n. d.	n. d.		negative
#46	n. d.	n. d.		n. d.	n. d.		negative
#47	n. d.	n. d.		n. d.	n. d.		negative
#48	n. d.	n. d.		n. d.	n. d.		negative
#49	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/A	/GTT CGG CTGCGGCGAGCGGTAT	+1/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#50	n. d.	n. d.		n. d.	n. d.		positive
#51	n. d.	n. d.		n. d.	n. d.		positive
#52	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/Cas9 sequence (AAGCACGAGCGCACCCATCTT...)	0/Cas9	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GTT CGG CTGCGGCGAGGAGTATCAGCTCACTCAAAG	0/0	negative
#53	n. d.	n. d.		n. d.	n. d.		positive
#54	n. d.	n. d.		n. d.	n. d.		positive
#55	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	n. d.	n. d.		negative
#56	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#57	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#58	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/A	/GTT CGG CTGCGGCGAGCGGTAT	+1/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#59	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#60	n. d.	n. d.		n. d.	n. d.		positive
#61	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#62	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#63	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#64	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#65	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	GTCGGTTGTCCTTGGT-----/	/GTT CGG CTGCGGCGAGGAGTATCAGCTCACTCAAAG	-17/0 (1nt overlapped)	negative
#66	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GTT CGG CTGCGGCGAGGAGTATCAGCTCACTCAAAG	0/0	negative
#67	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#68	CATGA-----/	/GTT CGG CTGCGGCGAGCGGTAT	-30/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCC- /	/GACCGAGCGCAGCGAGT CAGTG	-2/0 (1nt overlapped)	negative
#69	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GTT CGG CTGCGGCGAGCGGTAT	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GACCGAGCGCAGCGAGT CAGTG	0/0	negative
#70	CATGAAGCGGAAGGCACTATTACCTGCCCTTCA/	/GACCGAGCGCAGCGAGT CAGTG	0/0	GTCGGTTGTCCTTGGTGATGCGGCAGTCCCCGT/	/GTT CGG CTGCGGCGAGGAGTATCAGCTCACTCAAAG	0/0	negative

Supplementary Table S4 Summary of sequencing analysis of *VDR* alleles and functional assays of the *VDR* gene

Column1: clone number in which knock-in event was confirmed. Column2: the sequence detected by direct sequencing analysis of *VDR* gene in the knock-in clones

Column3-5: Summary of the results shown in Fig. 4

Clone	Indel mutations	VDR protein expression	<i>CYP24A1</i> induction	Reporter responsiveness
#1	delta 2bp	undetectable	no induction	nonresponsive
#5	delta 2bp, +1bp	undetectable	no induction	nonresponsive
#9	delta 1bp, +1bp			
#12	delta 2bp, delta 3bp			
#14	delta 1bp, delta 2bp			
#15	delta 1bp			
#16	delta 2 bp, Wild-type			
#17	+1bp			
#21	delta 1bp, +1bp			
#26	delta 13bp, delta 10bp, +4bp			
#29	delta 1bp, +1bp	undetectable	no induction	nonresponsive
#30	delta 1bp, delta 2bp			
#33	delta 120bp, delta 1bp, +1bp	undetectable	no induction	nonresponsive
#35	delta 1bp, delta 10bp	undetectable	no induction	
#38	delta 4bp			
#40	delta 1bp, delta 2bp	undetectable	no induction	
#41	delta 3bp			
#44	delta 1bp, delta 3bp			


Supplementary Table S5 Primers used in this study

Name	Sequence	Construct name	Backbone plasmid
Puro	5'-GTGGCGCGCCGGCCGCGAAGGATCTG-3' 5'-ACTTAATTAATAAGATACATTGATGAG-3'	pVKG1-Puro	pENTR
EGFP_pA	5'-ATTCTAGAGCTAGCGATGGTGAGCAAGGGCGAGG-3' 5'-ATTTAAATTCGAATT ATAAGATACATTGATGAGTT-3'	pGFP-RFPuro	pCDH
SV40promoter_BSD_pA	5'-CACCGGATCCGGCTGTGGAATGTG-3' 5'-CCAGACATGATAAGATACATTGATG-3'	pVKG1-BSD	pENTR
human_CYP24A1_PromoterS	5'-AAACTCGAGATTGTGCAAGCGCCGGCGGC-3' 5'-AAAGATATCATGTTCTATGCCAGGGAC-3'	pVDRE-Luc	pGL4.27
human_VDR	5'-AAAGAATTCATGGAGGCAATGGCGGCCAG-3' 5'-AAACTCGAGTCAGGAGATCTCATTGCCAAAC-3'	hVDR expression vector	pcDNA3FLAG

Name	Sequence	Primer name
Amplicon_1_for_VDR (Fig. 1d)	5'-TTCCTGTCTAGCGGTACGCG-3' 5'-GGTGGCCTCATGTCTTCTG-3'	VKG1_250R VDRgenome_del3F
Amplicon_2_for_VDR (Fig. 1d)	5'-GCCTATGGAAAAACGCCAGC-3' 5'-CCTTCATCATGCCGATGTCC-3'	VKG1_4561F VDRgenome_del1R
Amplicon_3_for_VDR (Fig. 1d)	5'-GCCTATGGAAAAACGCCAGC-3' 5'-GGTGGCCTCATGTCTTCTG-3'	VKG1_4561F VDRgenome_del3F
Amplicon_4_for_VDR (Fig. 1d)	5'-TTCCTGTCTAGCGGTACGCG-3' 5'-TGCCCAAACCTGCAGGAGAG-3'	VKG1_250R VDRgenome_del3R
Amplicon_5_for_VDR (Fig. 1d)	5'-ATGGCCGAGTTGAGCGGTTTC-3' 5'-AGACCCTTGCCCTGGTGGTC-3'	PuroF PuroR
Amplicon_6_for_VDR (Fig. 1d)	5'-GCCTATGGAAAAACGCCAGC-3' 5'-TTCCTGTCTAGCGGTACGCG-3'	VKG1_4561F VKG1_250R
Amplicon_1_for_AAVS1 (Fig. 2d)	5'-GGAAATGGGGGTGTGTCACC-3' 5'-GGGTCTTGTAGTTGCCGTCG-3'	AAVS_F5 EGFP_R2
Amplicon_2_for_AAVS1 (Fig. 2d)	5'-CCCTACCCCTTACCTCTC-3' 5'-GCAGAGCTCGTTTAGTGAACCG-3'	AAVS_R6 EGFP_F4
Amplicon_3_for_AAVS1 (Fig. 2d)	5'-GGAAATGGGGGTGTGTCACC-3' 5'-AACCGTCAGATCGCCTGGAG-3'	AAVS_F5 EGFP_F2
Amplicon_4_for_AAVS1 (Fig. 2d)	5'-ACCTCTCTAGTCTGTGCTAGC-3' 5'-GGGTCTTGTAGTTGCCGTCG-3'	AAVS_R5 EGFP_R2
Amplicon_5_for_AAVS1 (Fig. 2d)	5'-AACCGTCAGATCGCCTGGAG-3' 5'-GGGTCTTGTAGTTGCCGTCG-3'	EGFP_F2 EGFP_R2
Amplicon_Puro (Fig. 2d)	5'-ATGGCCGAGTTGAGCGGTTTC-3' 5'-AGACCCTTGCCCTGGTGGTC-3'	PuroF PuroR
VDR cleaving site (Fig. 3d)	5'-GGTGGCCTCATGTCTTCTG-3' 5'-TGCCCAAACCTGCAGGAGAG-3'	VDRgenome_del3F VDRgenome_del3R
hCYP24A1_qPCR (Fig. 4b)	5'-CAGCGAAGTGAACAATGGTCG-3' 5'-GCTCGACTGGAGTGACCATC-3'	hCYP24A1_qPCR_For hCYP24A1_qPCR_Rev
hACTB_qPCR (Fig. 4b)	5'-ATTGGCAATGAGCGGTTTC-3' 5'-CGTGGATGCCACAGGACT-3'	hACTB_qPCR_For hACTB_qPCR_Rev
Amplicon_BSD (Fig. S4a)	5'-CTGAAGACTACAGCGTCGCC-3' 5'-TTCTCATTCCGATCGCGACG-3'	BSD_F BSD_R
Amplicon_1_for_HR (Fig. S5a)	5'-TTCCTGTCTAGCGGTACGCG-3' 5'-TGCACCAGAGGATGGAGAG-3'	VKG1_250R HRgenome_F2
Amplicon_2_for_HR (Fig. S5a)	5'-GCCTATGGAAAAACGCCAGC-3' 5'-TCATGCTGTCCCAGTCCAC-3'	VKG1_4561F HRgenome_R1
Amplicon_3_for_HR (Fig. S5a)	5'-GCCTATGGAAAAACGCCAGC-3' 5'-GCGATGGGAACCTTGGGTAC-3'	VKG1_4561F HRgenome_F1
Amplicon_4_for_HR (Fig. S5a)	5'-TTCCTGTCTAGCGGTACGCG-3' 5'-TCATGCTGTCCCAGTCCAC-3'	VKG1_250R HRgenome_R1
Amplicon_5_for_HR (Fig. S5a)	5'-ATGGCCGAGTTGAGCGGTTTC-3' 5'-AGACCCTTGCCCTGGTGGTC-3'	PuroF PuroR
Amplicon_6_for_HR (Fig. S5a)	5'-GCCTATGGAAAAACGCCAGC-3' 5'-TTCCTGTCTAGCGGTACGCG-3'	VKG1_4561F VKG1_250R


Supplemental information

Figure 1d




Supplemental information

Figure 2d




Supplemental information

Figure 3a



Supplimental information


Figure 3b




Supplemental information

Figure 4a


α VDR




α VDR / Ladder marker




α Hsp90




α Hsp90 / Ladder marker



α β -ACT




α β -ACT / Ladder marker




Supplemental information

Supplementary Figure S4a


Amplicon 1




Amplicon 2



Amplicon 3




Amplicon 4




M : 100bp ladder marker


Amplicon Puro



Amplicon BSD




Amplicon 6



Supplemental information

Supplementary Figure S4c


α VDR




α VDR / Ladder marker




α Hsp90




α Hsp90 / Ladder marker



$\alpha\beta$ -ACT




$\alpha\beta$ -ACT / Ladder marker



Supplemental information

Supplementary Figure S5a


Amplicon 1




Amplicon 2



Amplicon 3




Amplicon 4



M : 100bp ladder marker

Amplicon 5




Amplicon 6




Supplemental information

Supplementary Figure S5e


α HR




α HR / Ladder marker




α Hsp90



α Hsp90 / Ladder marker



$\alpha\beta$ -ACT



$\alpha\beta$ -ACT / Ladder marker

